Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2015-02-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1500712112PMID 25730880PMCID PMC4352777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

  2014cited by this paper
• Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

  2014cited by this paper
• Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

  2014cited by this paper
• Pembrolizumab: First Global Approval

  2014cited by this paper
• Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

  2014cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1

  2007cited by this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cited by this paper
• Building of the Tetraspanin Web: Distinct Structural Domains of CD81 Function in Different Cellular Compartments

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• 618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target

  2005cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Mouse 4T1 Breast Tumor Model

  2000cited by this paper
• A novel orthotopic model of breast cancer metastasis to bone

  1999cited by this paper
• The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

  1996cited by this paper

• A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma

  2026cites this paper
• LED light inhibits malignant tumors via high-density nanolocalized photothermal effects on cell membranes

  2026cites this paper
• Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy.

  2026cites this paper
• Lipid nanoparticle-mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy.

  2026cites this paper
• Dual-Enzyme-Instructed Peptide Self-Assembly to Boost Immunogenic Cell Death by Coordinating Intracellular Calcium Overload and Chemotherapy.

  2025cites this paper
• Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

  2025cites this paper
• Plasma Membrane Targeted Photodynamic Nanoagonist to Potentiate Immune Checkpoint Blockade Therapy by Initiating Tumor Cell Pyroptosis and Depleting Infiltrating B Cells

  2025cites this paper
• Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis

  2025cites this paper
• Tumor-expressed GPNMB orchestrates Siglec-9+ TAM polarization and EMT to promote metastasis in triple-negative breast cancer.

  2025cites this paper
• Molecular targets and therapies associated with poor prognosis of triple-negative breast cancer (Review)

  2025cites this paper
• Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer

  2025cites this paper
• Bruton’s tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system

  2025cites this paper
• Tumor-specific surface marker–independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry

  2025cites this paper
• Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation

  2025cites this paper
• Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review

  2025cites this paper
• Identification of a Prognostic Signature Based on Tumor-Infiltrating B Lymphocyte mRNA in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy

  2025cites this paper
• Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy

  2025cites this paper
• A novel TOX-nanoluciferase reporter mouse for exploring modulators of T cell exhaustion.

  2025cites this paper
• ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy

  2025cites this paper
• Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells

  2025cites this paper
• Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma

  2024cites this paper
• Neutralizing IL-16 enhances the efficacy of targeting Aurora-A therapy in colorectal cancer with high lymphocyte infiltration through restoring anti-tumor immunity

  2024cites this paper
• Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

  2024cites this paper
• Engineering Modular Peptide Nanoparticles for Ferroptosis-Enhanced Tumor Immunotherapy.

  2024cites this paper
• High‐Efficiency Gold Nanoaggregates for NIR LED‐Driven Sustained Mild Photothermal Therapy Achieving Complete Tumor Eradication and Immune Enhancement

  2024cites this paper
• The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models

  2024cites this paper
• Unzippable Siamese Nanoparticles for Programmed Two‐Stage Cancer Immunotherapy

  2024cites this paper
• Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment.

  2024cites this paper
• An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine

  2024cites this paper
• PAMAM-Based Polymeric Immunogenic Cell Death Inducer To Potentiate Cancer Immunotherapy.

  2024cites this paper
• Manipulating the Crosstalk between Cancer and Immunosuppressive Cells with Phototherapeutic Gold‐Nanohut for Reprogramming Tumor Microenvironment

  2024cites this paper
• Engineering Bimetallic Polyphenol for Mild Photothermal Osteosarcoma Therapy and Immune Microenvironment Remodeling by Activating Pyroptosis and cGAS‐STING Pathway

  2024cites this paper
• The Dual Role of B Cells in the Tumor Microenvironment: Implications for Cancer Immunology and Therapy

  2024cites this paper
• iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

  2024cites this paper
• Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance

  2024cites this paper
• Immune-enhanced and tumor-targeted PDT cascade therapy for oral squamous cell carcinoma utilizing a carrier-free BRD4 inhibitor/PDT agent nanocomplex

  2024cites this paper
• Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy

  2024cites this paper
• Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential

  2024cites this paper
• Mucosal tumor vaccination delivering endogenous tumor antigens protects against pulmonary breast cancer metastases

  2024cites this paper
• IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy

  2024cites this paper
• Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

  2024cites this paper
• Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy

  2024cites this paper
• A Highly Tumor Permeating DNA Nanoplatform for Efficient Remodeling of Immunosuppressive Tumor Microenvironments.

  2024cites this paper
• Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor

  2024cites this paper
• Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration

  2024cites this paper
• Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

  2023cites this paper
• Practical Management of Richter Transformation in 2023 and Beyond.

  2023cites this paper
• Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient

  2023cites this paper
• Genetically Engineered Nanovesicles Mobilize Synergistic Antitumor Immunity by ADAR1 Silence and PDL1 Blockade.

  2023cites this paper
• Schottky Heterojunction Realizes In Situ Vaccine‐Like Antitumor Efficacy and Microenvironment Remodeling Upon Near‐Infrared Laser Response in Cold Tumors

  2023cites this paper
• Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer

  2023cites this paper
• Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells

  2023cites this paper
• A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?

  2023cites this paper
• Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies.

  2023cites this paper
• Degrading the signal amplifier: ITK as a target for targeted protein degradation.

  2023cites this paper
• SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.

  2023cites this paper
• Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

  2023cites this paper
• Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

  2023cites this paper
• Tumor nano-lysate activates dendritic cells to evoke a preventative immune response.

  2023cites this paper
• In Situ Nanofiber Patch Boosts Postoperative Hepatocellular Carcinoma Immune Activation by Trimodal Combination Therapy

  2023cites this paper
• Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study

  2023cites this paper
• PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

  2023cites this paper
• The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration

  2023cites this paper
• Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.

  2023cites this paper
• Identification of potential susceptibility genes in patients with primary Sjögren’s syndrome-associated pulmonary arterial hypertension through whole exome sequencing

  2023cites this paper
• Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models

  2023cites this paper
• Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents

  2023cites this paper
• Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition

  2023cites this paper
• Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK

  2023cites this paper
• Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy

  2023influential citation
• Contrasting roles of different mismatch repair proteins in basal-like breast cancer

  2023cites this paper
• NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance.

  2023cites this paper
• Recent advances in cancer cell bionic nanoparticles for tumour therapy

  2023cites this paper
• Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

  2023cites this paper
• Methylation-related genes involved in renal carcinoma progression

  2023cites this paper
• Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage.

  2022cites this paper
• Recent development of BTK-based dual inhibitors in the treatment of cancers.

  2022cites this paper
• Nanotechnology-based Multifunctional Vaccines for Cancer Immunotherapy

  2022cites this paper
• Challenges of CAR T-cell Therapy in CLL: Lessons Learned.

  2022cites this paper
• A Size/Charge/Targeting Changeable Nano-booster to Realize Synergistic Photodynamic-Immunotherapy with High Safety

  2022cites this paper
• Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

  2022cites this paper
• Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy

  2022cites this paper
• Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.

  2022cites this paper
• BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report

  2022cites this paper
• Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

  2022cites this paper
• 90Y-Labeled Gold Nanoparticle Depot (NPD) Combined with Anti-PD-L1 Antibodies Strongly Inhibits the Growth of 4T1 Tumors in Immunocompetent Mice and Induces an Abscopal Effect on a Distant Non-Irradiated Tumor.

  2022cites this paper
• Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates

  2022cites this paper
• In vivo bioluminescence imaging of granzyme B activity in tumor response to cancer immunotherapy.

  2022cites this paper
• Chemotherapy Mediated by Biomimetic Polymeric Nanoparticles Potentiates Enhanced Tumor Immunotherapy via Amplification of Endoplasmic Reticulum Stress and Mitochondrial Dysfunction

  2022cites this paper
• Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo

  2022cites this paper
• Clinical application of cell‐based therapies opportunities and challenges

  2022cites this paper
• Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect

  2022cites this paper
• Emerging Therapies for the Management of Richter Transformation.

  2022cites this paper
• Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

  2022influential citation
• Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

  2022cites this paper
• CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints

  2022cites this paper
• Gene-guided OX40L anchoring to tumor cells for synergetic tumor "self-killing" immunotherapy.

  2022cites this paper
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

  2022cites this paper
• Focused Acoustic Vortex-Regulated Composite Nanodroplets Combined with Checkpoint Blockade for High-Performance Tumor Synergistic Therapy.

  2022cites this paper